OBIRINSNCT05786768
Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome
StatusActive, Not Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 25 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Primary and study completion dates moved earlier to Jun 30, 2027
- Site details revised
- Publications: details revised at 3 of 3 entries
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Start date changed from estimate of May 15, 2023 to Oct 18, 2023
- Primary completion date: May 15, 2027 to Oct 18, 2027
- Study completion date: Dec 15, 2027 to Dec 31, 2027
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Occurrence of a relapse within 12 months following the initiation of treatment
Timeframe: 12 months
Secondary (8)
Occurrence of a relapse within 24 months
Time to B-cell depletion
Duration of relapse-free survival after B-cell reconstitution
Cumulative steroid courses and second line immunosuppressive treatments in patients with relape
Safety associated with drug infusion
Show 3 moreShow less
Efficiency defined as incremental cost-effectiveness ratio in cost per relapse prevented
Budgetary impact defined as costs and health gains incurred with the generalization of the obinutuzumab strategy
Detection of Antidrug Antibodies
Arms and interventions
Rituximab 375 mg/m2Active comparator
single infusion of Rituximab (375 mg/m2)
Obinutuzumab 300 mg/1.73 m2Experimental
single infusion of Obinutuzumab 300 mg/1.73 m2
Drugs: single infusion of Rituximab, single infusion of Obinutuzumab
Sites
1 site in 1 country
- Robert Debre HospitalParis, France